Discrete Particles In Supporting Matrix Patents (Class 424/469)
-
Patent number: 10881616Abstract: The invention relates to a process of preparing a salt of an active pharmaceutical ingredient, the process comprising providing a blend of an active pharmaceutical ingredient and a salt forming substance, mixing the blend, optionally in the presence of added water, to react the active pharmaceutical ingredient with the salt forming substance to provide the salt of the active pharmaceutical ingredient; wherein when the active pharmaceutical ingredient is acidic, the salt forming substance is a base and the pKa difference between the acidic active pharmaceutical ingredient and the base is greater than 1, typically greater than 2 or preferably greater than 3; or when the active pharmaceutical ingredient is basic, the salt forming substance is an acid and the pKa difference between the basic active pharmaceutical ingredient and the acid is greater than 1, typically greater than 2 or preferably greater than 3.Type: GrantFiled: January 16, 2017Date of Patent: January 5, 2021Assignees: Cubic Pharmaceuticals Ltd., University of GreenwichInventors: Mohammed Maniruzzaman, Saumil Kiritkumar Bhatt, Anwar Ali, Arun Jangra
-
Patent number: 10736829Abstract: The present invention relates primarily to the use of certain hydroxybenzoic acid amides or the salts or mixtures thereof for masking an unpleasant taste impression, preferably of a bitter, adstringent, dusty, dry, floury, rancid, metallic and/or cardboard taste or aftertaste, of one or more unpleasant-tasting peptides or of certain amino acid mixtures. The invention further relates to a corresponding method for masking unpleasant taste impressions and to novel preparations.Type: GrantFiled: September 30, 2015Date of Patent: August 11, 2020Assignee: SYMRISE AGInventors: Joachim Hans, Jakob Ley, Kathrin Langer, Susanne Paetz
-
Patent number: 10716761Abstract: Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.Type: GrantFiled: July 23, 2018Date of Patent: July 21, 2020Assignee: Alcresta Therapeutics, Inc.Inventors: Eric First, David Widom
-
Patent number: 10702477Abstract: The present invention refers to a process for preparing granules or particles comprising afatinib dimaleate, comprising the steps of providing afatinib dimaleate and at least one pharmaceutically acceptable excipient, and preparing granules or particles involving the use of at least one solvent selected from organic solvent and water, wherein all pharmaceutically acceptable excipients used in the process for preparing granules or particles have neutral or acidic properties, and wherein afatinib dimaleate has a solubility of at least 5 mg/ml in said at least one solvent. The present invention further refers to granules or particles comprising afatinib dimaleate that are prepared according to this process. Additionally, the present invention refers to a process for preparing a pharmaceutical composition comprising afatinib dimaleate, as well as to an adsorbate comprising afatinib dimaleate.Type: GrantFiled: October 11, 2016Date of Patent: July 7, 2020Inventors: Jan Pelipenko, Katja Kristan, Marko Oblak, Miha Homar, Rok Grahek
-
Patent number: 10688060Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.Type: GrantFiled: April 30, 2019Date of Patent: June 23, 2020Assignee: Purdue Pharma L.P.Inventors: Ricardo Alberto Vargas Rincon, Joseph Reiz
-
Patent number: 10300021Abstract: The present invention provides an intraorally rapidly disintegrating tablet that can be formed using an ordinary apparatus, that has hardness with no practical problem and that disintegrates rapidly with good feeling in the oral cavity. The present invention is intraorally rapidly disintegrating tablet produced by compression molding of a granule coated with a disintegrant, in which the granule contains a disintegrant also inside thereof and a drug except ambroxol hydrochloride inside and/or outside thereof.Type: GrantFiled: November 14, 2006Date of Patent: May 28, 2019Assignee: Teijin Pharma LimitedInventors: Tomoya Akutagawa, Masahiko Narasaki
-
Patent number: 10238102Abstract: A composite particle comprises i) an hydrophobic particle that adheres to the cuticle of one or more species of animal infesting arthropod; and ii) at least one organic chemical compound admixed therewith, wherein the said organic chemical is capable of controlling the population of at least one animal infesting arthropod species. Experiments proved the efficacy of the particle, for example in powder form, in relation to a variety of arthropods, for example red poultry mites.Type: GrantFiled: April 12, 2011Date of Patent: March 26, 2019Assignee: Exosect LimitedInventors: Clare Gillian Storm, Nicola Jane Huggett
-
Patent number: 10226462Abstract: The present invention relates to a method of treating or preventing hair loss or excessive hair shedding in a subject by administering to a subject an oral dose of minoxidil. In particular, the present invention relates to a method of treating telogen effluvium in a subject by administering to a subject an oral dose of minoxidil.Type: GrantFiled: October 29, 2015Date of Patent: March 12, 2019Assignee: Samson Clinical Pty LtdInventor: Rodney Sinclair
-
Patent number: 10179130Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.Type: GrantFiled: March 15, 2013Date of Patent: January 15, 2019Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
-
Patent number: 10172828Abstract: The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.Type: GrantFiled: December 22, 2017Date of Patent: January 8, 2019Assignee: iCeutica Pty Ltd.Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H. William Bosch
-
Patent number: 10117449Abstract: The present invention relates to a process for the production of extruded formulations (=extrudates) comprising dispersion droplets, to such formulations as well as to the use of such formulations in food, feed, personal care applications.Type: GrantFiled: February 27, 2013Date of Patent: November 6, 2018Assignee: DSM IP ASSETS B.V.Inventors: Petrus Henricus Maria Elemans, Adrian Willem Meesen, Alexandra Teleki, Bruno Leuenberger
-
Patent number: 10080721Abstract: The invention relates to a hot-melt extruded pharmaceutical dosage form with controlled release of a pharmacologically active ingredient (A) embedded in a matrix comprising a polymer (C), the dosage form exhibiting a breaking strength of at least 300 N and having an oblong shape comprising a longitudinal direction of extension, a transversal direction of extension orthogonal to the longitudinal direction of extension, a front side, an opposite back side and a circumferential rim between said front and back side; wherein the core of the pharmaceutical dosage form has a morphological orientation caused by hot-melt extrusion that is substantially orthogonal to the longitudinal direction of extension of the dosage form; and/or the release per area of the pharmacologically active ingredient (A) through the front side and the opposite back side is faster than the release through the circumferential rim.Type: GrantFiled: July 21, 2010Date of Patent: September 25, 2018Assignee: GRUENENTHAL GMBHInventors: Lutz Barnscheid, Eric Galia
-
Patent number: 9943489Abstract: The present invention provides various pharmaceutical compositions, in particular for oral administration, formulated for extended release of active compounds useful in the treatment of neurodegenerative diseases, in particular Parkinson's disease, and injuries to the nervous system. The active compound comprised within these compositions is preferably selected from N-propargyl-1-aminoindan, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, more preferably rasagiline or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 3, 2011Date of Patent: April 17, 2018Assignee: PHARMATWOB LTD.Inventors: Yoram Sela, Nurit Livnah, Itschak Lamensdorf, Tomer Madmon
-
Patent number: 9820948Abstract: The present invention concerns a new composition based on pellets of lipoic acid in a lipophilic medium, if necessary combined with other active ingredients.Type: GrantFiled: October 23, 2008Date of Patent: November 21, 2017Assignee: Olon S.p.A.Inventors: Paolo Magri', Antonio Nardi, Annibale Salvi, Flavio Villani
-
Patent number: 9789065Abstract: A process for producing solid oral dosage forms with controlled active ingredient release, comprising a mixture of a) at least one active ingredient, and b) a preformulated mixture of polyvinyl acetate and polyvinylpyrrolidone, wherein the mixture is obtained by joint processing of components a) and b) in an extruder at temperatures between 50° and 200° C.Type: GrantFiled: October 2, 2009Date of Patent: October 17, 2017Assignee: BASF SEInventors: Karl Kolter, Angelika Maschke
-
Patent number: 9744136Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.Type: GrantFiled: September 11, 2013Date of Patent: August 29, 2017Assignee: Purdue Pharma L.P.Inventor: Haiyong Hugh Huang
-
Patent number: 9743688Abstract: Flavorants are emulsified in tobacco-derived lipids and encapsulated with biopolymers and polysaccharides. The emulsions include oil-in-water emulsions, oil-in-water-in-oil emulsions, water-in oil emulsions, or water-in-oil-in-water emulsions, and optionally include ethanol and/or propylene glycol in an oil phase.Type: GrantFiled: March 25, 2011Date of Patent: August 29, 2017Assignee: Philip Morris USA Inc.Inventors: Tapashi Sengupta, Munmaya K. Mishra, Douglas A. Fernandez, William R. Sweeney, Tony M. Howell
-
Patent number: 9682043Abstract: This invention pertains to a method of preparing mixed phase co-crystals of active agents with one or more materials that allows the modification of the active agent to a new physical/crystal form with unique properties useful for the delivery of the active agent, as well as compositions comprising the mixed phase co-crystals.Type: GrantFiled: December 9, 2004Date of Patent: June 20, 2017Assignee: MedCrystalForms, LLCInventor: David Goldman
-
Patent number: 9572779Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.Type: GrantFiled: February 17, 2016Date of Patent: February 21, 2017Assignee: Purdue Pharma L.P.Inventor: Haiyong Hugh Huang
-
Patent number: 9545402Abstract: A pharmaceutical composition for oral administration comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one monolactate monohydrate, a filler in an amount of 15 to 70% by weight, a disintegrant in an amount of less than 15% by weight, a glidant and/or a lubricant in an amount of 0.1 to 10% by weight wherein the amounts by weight are based on the total weight of the composition.Type: GrantFiled: June 29, 2011Date of Patent: January 17, 2017Assignee: Novartis AGInventors: Jeewan Thakur, Zhihui Qiu
-
Patent number: 9522118Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.Type: GrantFiled: February 17, 2016Date of Patent: December 20, 2016Assignee: Purdue Pharma L.P.Inventor: Haiyong Hugh Huang
-
Patent number: 9511029Abstract: The present invention provides an intraorally rapidly disintegrating tablet that can be formed using an ordinary apparatus, that has hardness with no practical problem and that disintegrates rapidly with good feeling in the oral cavity. The present invention is intraorally rapidly disintegrating tablet produced by compression molding of a granule coated with a disintegrant, in which the granule contains a disintegrant also inside thereof and a drug except ambroxol hydrochloride inside and/or outside thereof.Type: GrantFiled: September 18, 2009Date of Patent: December 6, 2016Assignee: Teijin Pharma LimitedInventors: Tomoya Akutagawa, Masahiko Narasaki
-
Patent number: 9393206Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.Type: GrantFiled: September 11, 2013Date of Patent: July 19, 2016Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.Inventor: Haiyong Hugh Huang
-
Patent number: 9375482Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.Type: GrantFiled: April 22, 2014Date of Patent: June 28, 2016Assignee: University of GenevaInventors: Michael Moller, Thomas Trimaille, Robert Gurny
-
Patent number: 9345715Abstract: Provided herein are methods and compositions for treating metabolic diseases and conditions associated with metabolic diseases.Type: GrantFiled: November 9, 2012Date of Patent: May 24, 2016Assignee: SATIOGEN PHARMACEUTICALS, INC.Inventors: Andrew A. Young, Bronislava Gedulin, Howard E. Greene
-
Patent number: 9320717Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.Type: GrantFiled: March 30, 2015Date of Patent: April 26, 2016Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
-
Patent number: 9278074Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.Type: GrantFiled: March 30, 2015Date of Patent: March 8, 2016Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
-
Patent number: 9271939Abstract: The present invention provides stabilized prolonged release pharmaceutical compositions comprising atypical antipsychotic drug like paliperidone or pharmaceutically acceptable salts thereof without incorporating surfactant and/or water penetration enhancer. Such compositions are preferably in the form of a matrix wherein one or more release controlling agents are present in and/or on the matrix. Further, such compositions comprise one or more release controlling agent and exhibits desired in vitro release of drug with or without lag period. The invention also provides a process for the preparation of such compositions.Type: GrantFiled: March 11, 2011Date of Patent: March 1, 2016Assignee: Inventia Healthcare Private LimitedInventors: Sunil Deviprasad Tiwari, Vijayendrakumar Virendrakumarji Redasani, Prasad Shrikantrao Joshi, Vaibhav Narayan Sawarkar, Ankur Janak Shah
-
Patent number: 9233078Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a poorly aqueous soluble non-ionizable polymer, and an amine-functionalized methacrylate copolymer.Type: GrantFiled: December 5, 2008Date of Patent: January 12, 2016Assignee: Bend Research, Inc.Inventors: Corey J. Bloom, Marshall David Crew, Warren Kenyon Miller
-
Patent number: 9198862Abstract: Disclosed herein is a dispersible tablet composition including a pharmacologically active ingredient and at least one excipient that reduces the sedimentation rate of the active ingredient and a process for preparing the same.Type: GrantFiled: July 24, 2006Date of Patent: December 1, 2015Assignee: Rubicon Research Private LimitedInventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anilkumar Surendrakumar Gandhi, Pradnya Bagde, Varsha Barve
-
Patent number: 9192679Abstract: The invention relates to a novel galenical system for taste masking, protecting an active substance, in particular in an acid medium, modulating releasing properties, masking mucous irritability and toxicity of certain active substances, for preparing aqueous forms which have a masked taste, are stable and pH independent. Said invention also relates, in particular to a galenical system which is embodied in the form of lipidic solid particles and strictly hydrophobic and devoid of water, surface active agents, emulsifiers, solvent traces and which is characterized in that it comprises at least one type of hydrophobic wax and at least one type of fatty non-neutralised acid.Type: GrantFiled: October 27, 2014Date of Patent: November 24, 2015Assignee: Capsugel France SASInventors: Karim Ioualalen, Rosanne Raynal
-
Patent number: 9192641Abstract: The current invention is a supplement made from a combination of herbs, vitamins, amino acids which in the preferred embodiment is a 100% vegetarian liquid capsules that are ingested allow for rapid absorption. The components of the supplement can be mint or menthol such as peppermint or spearmint, Methyl B12 or B12, Niacin, Guarana, Dimethylaminoethanol, Acetyl-L-carnitine or ALCAR, Ocimum tenuiflorum, one or more teas such as green tea, white tea or black tea, Ginkgo, Rhodiola rosea, phosphatidylserine, Tyrosine, L-Alpha Glycerylphosphorylcholine, Citicoline (INN), Huperzine A, and Vinpocetine.Type: GrantFiled: October 6, 2014Date of Patent: November 24, 2015Inventor: Shaahin Cheyene
-
Patent number: 9168226Abstract: The present invention provides an injectable particle comprising dasatinib acetate and a hyaluronic acid. The hyaluronic acid may be acetylated or sulfated. The particle is for the use of cancer therapy. The injectable particle may further comprises an acid, wherein the acid is dispersed evenly in the matrix of the injectable particle.Type: GrantFiled: August 7, 2015Date of Patent: October 27, 2015Inventor: David Wong
-
Patent number: 9125948Abstract: The present invention provides a method and composition for loading one or more drugs in a solution onto one or more ion exchange resin particles to form a drug-loaded resin particle. The drug-loaded resin particle is separated from the solution and dried before recombining the drug-loaded resin particle with the solution to load more drugs onto the drug-loaded resin particle from the solution.Type: GrantFiled: December 10, 2010Date of Patent: September 8, 2015Assignee: Coating Place, Inc.Inventors: Harlan Hall, J. Scott Madsen
-
Patent number: 9107835Abstract: The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises an enteric coated aspirin active ingredient, and preferably a lightly compressed matrix comprising directly compressible carbohydrate(s) and at least one sweetener.Type: GrantFiled: May 12, 2014Date of Patent: August 18, 2015Assignee: McNeil-PPC, Inc.Inventors: Manoj N. Shah, James S. Beahm, Robert Shen
-
Patent number: 9107825Abstract: A hydrophobic drug delivery system that includes a plant derived sterol (stanol) or a sterol (stanol) derived ester, an emulsifier and an active, hydrophobic drug, all dissolved and then dried to form a liposome delivery system.Type: GrantFiled: December 17, 2012Date of Patent: August 18, 2015Assignee: ZOMANEX, LLCInventor: Curtis A. Spilburg
-
Patent number: 9078900Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active risperidone at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of risperidone to tissues or organs.Type: GrantFiled: September 29, 2009Date of Patent: July 14, 2015Assignee: BRAEBURN PHARMACEUTICALS BVBA SPRLInventors: Petr Kuzma, Harry Quandt
-
Patent number: 9050258Abstract: The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations.Type: GrantFiled: August 13, 2013Date of Patent: June 9, 2015Assignee: AstraZeneca ABInventors: Admassu Abebe, Kyle Martin, Jatin M. Patel, Divyakant Desai, Peter Timmins
-
Publication number: 20150110870Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.Type: ApplicationFiled: December 23, 2014Publication date: April 23, 2015Inventors: Benjamin Oshlack, Hua-Pin HUANG, John K. Masselink, Alfred Tonelli
-
Publication number: 20150110871Abstract: The present invention relates to a gastric retentive tablet composition comprising: (1) coated particles essentially consisting of a drug and an amino methacrylate copolymer, (2) a methacrylic acid copolymer and (3) an excipient, wherein items 1, 2, and 3 are blended together, and then compressed into a gastric retentive tablet. Thus, the coated particles (item 1), a methacrylic acid copolymer and the excipient are evenly distributed in the tablet. The excipient is selected from a group consisting of a retarding agent, a binder, a filler, a chelating agent, a diluent, a disintegrant, a lubricant, a colorant, a solubilizing agent, or a mixture thereof. The coated particles (item 1) do not contain methacrylic acid polymer.Type: ApplicationFiled: January 3, 2015Publication date: April 23, 2015Inventor: David Wong
-
Patent number: 9000046Abstract: Gastric retentive dosage forms for sustained release of acamprosate are described which may allow once- or twice-daily dosing for both acute and long-term treatment of a disorder including alcohol dependence, tinnitus, sleep apnea, Parkinson's disease, levodopa-induced dyskinesias in Parkinson's disease, Alzheimer's disease, Huntington's disease, Amyotrophic lateral sclerosis, Cortical spreading depression, migraine, schizophrenia, anxiety, tardive dyskinesia, spasticity, multiple sclerosis, various types pain, or binge eating. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.Type: GrantFiled: September 28, 2011Date of Patent: April 7, 2015Assignee: Depomed, Inc.Inventors: Bret Berner, Cuiping Chen
-
Patent number: 8999386Abstract: An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.Type: GrantFiled: June 10, 2014Date of Patent: April 7, 2015Assignee: TRIS Pharma, Inc.Inventors: Yu-Hsing Tu, Ashok Perumal, Kalyan Kathala
-
Patent number: 8968776Abstract: The invention provides new benzimidazole compositions, comprising: (a) a core containing said benzimidazole active ingredient; (b) an intermediate layer; and (c) an enteric layer; said core being substantially free of binder. The invention also provides a process for manufacturing the composition of the invention.Type: GrantFiled: May 16, 2013Date of Patent: March 3, 2015Assignee: UCB, Inc.Inventors: Pawan Seth, Benoît Schmitt
-
Patent number: 8962019Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.Type: GrantFiled: October 15, 2010Date of Patent: February 24, 2015Assignee: Angelini Pharma, Inc.Inventors: Sonia Gervais, Damon Smith, Pauline Contamin, Rachid Ouzerourou, My Linh Ma
-
Patent number: 8962022Abstract: The present invention is directed to compositions of taste-masked microparticles comprising a substituted benzhydrylpiperazine coated and a taste-masking layer comprising a water-insoluble polymer and a gastrosoluble polymer, and methods of making such taste-masked microparticles. The present invention is also directed to stable orally disintegrating compositions comprising taste-masked microparticles of a substituted benzhydrylpiperazine and rapidly dispersing granules, and methods of making such orally disintegrating compositions.Type: GrantFiled: March 27, 2008Date of Patent: February 24, 2015Assignee: Aptalis Pharmatech, Inc.Inventor: Gopi Venkatesh
-
Publication number: 20150037409Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.Type: ApplicationFiled: October 21, 2014Publication date: February 5, 2015Inventors: Benjamin Oshlack, Hua-Pin HUANG, John K. Masselink, Alfred Tonelli
-
Patent number: 8927013Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a pharmaceutically active agent that can be the same or different from the pharmaceutically active agent in the microparticles. The composition further comprises a superabsorbent material disposed within the first layer, the second layer, or both the first layer and the second layer. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the composition.Type: GrantFiled: March 3, 2014Date of Patent: January 6, 2015Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe LimitedInventors: Miloud Rahmouni, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Ali Bichara
-
Patent number: 8927016Abstract: This invention provides a production method for a solid sustained-release preparation, characterized in that a sustained-release preparation (a sustained-release preparation suspension) is freeze-dried in a freeze-drying container whose inner face is partially or totally coated with an ice layer or water-repelling base material.Type: GrantFiled: November 23, 2010Date of Patent: January 6, 2015Assignee: Takeda Pharmaceutical Company LimitedInventors: Hisayoshi Shimizu, Muneo Nonomura, Tomomichi Futo, Kei Mukai
-
Patent number: 8927014Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a superabsorbent material. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material creates a hard gel that traps the microparticles. The hard gel and microparticles provide controlled release of the pharmaceutically active agent.Type: GrantFiled: June 16, 2014Date of Patent: January 6, 2015Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe LimitedInventors: Miloud Rahmouni, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Ali Bichara
-
Patent number: 8920833Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the coreswells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.Type: GrantFiled: March 3, 2014Date of Patent: December 30, 2014Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe LimitedInventors: Miloud Rahmouni, Angela Ferrada, Fouzia Soulhi, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Bobby-Ernst Boursiquot, Ali Bichara